Outcomes with frontline immune checkpoint inhibitors among individuals with <i>BRAF</i>-mutant non-small cell lung cancer.

ABSTRACT:

Background

Oncogenic BRAF mutations affect ~4% of non-small cell lung cancer (NSCLC). Class I mutations (i.e., V600) are typically responsive to BRAF/MEK inhibitors, while non-Class I are often resistant. The role of immune checkpoint inhibitors (ICIs) as first-line therapy in BRAF-mutant NSCLC remains unclear.

Methods

We retrospectively analyzed patients with BRAF-mutant NSCLC treated at Moffitt Cancer Center from January 1, 2012, to August 9, 2023. Demographics, biomarker (e.g., PD-L1, molecular profile), and treatment data were collected. Progression-free survival (PFS) and overall survival (OS) were estimated using standardized real-world endpoints.

Results

Among 122 individuals, 54 had Class I and 68 had non-Class I mutations. For Class I mut

SUBMITTER: Marin-Acevedo JA 

PROVIDER: S-EPMC12727587 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature